for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ロシュ・ホールディング

ROG.S

現在値

340.40CHF

変化

-2.20(-0.64%)

出来高

873,762

本日のレンジ

338.60

 - 

342.50

52週レンジ

290.55

 - 

374.70

∙ 約20分前の相場を表示しています。

適時開示

Roche Launches Three Respiratory Test Panels On Cobas 6800/8800 Systems In CE Markets

Sept 22 (Reuters) - Roche Holding AG <ROG.S>::ROCHE LAUNCHES THREE RESPIRATORY TEST PANELS ON COBAS 6800/8800 SYSTEMS IN CE MARKETS TO HELP IDENTIFY MULTIPLE PATHOGENS WITH OVERLAPPING SYMPTOMS IN PATIENTS.THREE NEW MOLECULAR DIAGNOSTIC TEST PANELS FOR INFLUENZA AND OTHER COMMON RESPIRATORY ILLNESSES CAN BE RUN TOGETHER OR ALONE USING ONE PATIENT SAMPLE..FLEXIBLE SYNDROMIC TESTING TAILORED TO PATIENT NEEDS REDUCES UNNECESSARY TESTING AND PROVIDES CLINICIANS WITH ACTIONABLE INSIGHTS SOONER WHEN COMPARED TO CONVENTIONAL METHODS..

Roche Says FDA Approves Priority Review, For Faricimab For Vision Loss

Sept 15 (Reuters) - :ROCHE SAYS FDA ACCEPTS APPLICATION FOR ROCHE’S FARICIMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA.ROCHE SAYS FDA APPROVES PRIORITY REVIEW, FOR FARICIMAB FOR THE TREATMENT OF NEOVASCULAR OR “WET” AGE-RELATED MACULAR DEGENERATION (NAMD) AND DIABETIC MACULAR EDEMA (DME). THE FDA HAS ALSO ACCEPTED THE COMPANY’S SUBMISSION FOR DIABETIC RETINOPATHY..ROCHE SAYS IF APPROVED FARICIMAB WILL BE THE FIRST AND ONLY BISPECIFIC ANTIBODY DESIGNED FOR THE EYE.

Adaptimmune Enters Into Strategic Collaboration With Genentech

Sept 7 (Reuters) - AdaptImmune <ADAP.O>: :ADAPTIMMUNE ENTERS INTO STRATEGIC COLLABORATION WITH GENENTECH TO RESEARCH, DEVELOP, COMMERCIALIZE CANCER-TARGETED ALLOGENEIC T-CELL THERAPIES.ADAPTIMMUNE - COLLABORATION COVERS DEVELOPMENT OF NOVEL ALLOGENEIC PERSONALIZED CELL THERAPY PLATFORM.ADAPTIMMUNE - GENENTECH WILL BE RESPONSIBLE FOR INPUT TCRS & SUBSEQUENT CLINICAL DEVELOPMENT, COMMERCIALIZATION.ADAPTIMMUNE - WILL RECEIVE UPFRONT PAYMENT OF $150 MILLION, ADDITIONAL PAYMENTS OF $150 MILLION OVER 5 YRS, UNLESS AGREEMENT IS EARLIER TERMINATED.ADAPTIMMUNE - CO TO BE RESPONSIBLE FOR DEVELOPING CLINICAL CANDIDATES USING ITS IPSC DERIVED ALLOGENEIC PLATFORM TO PRODUCE T-CELLS.ADAPTIMMUNE - COLLABORATION COVERS RESEARCH & DEVELOPMENT OF “OFF-THE-SHELF” CELL THERAPIES FOR UP TO 5 SHARED CANCER TARGETS.ADAPTIMMUNE - MAY BE ELIGIBLE TO RECEIVE MILESTONES PAYMENTS POTENTIALLY EXCEEDING $3 BILLION IN AGGREGATE VALUE.ADAPTIMMUNE - WILL ALSO RECEIVE TIERED ROYALTIES ON NET SALES IN MID-SINGLE TO LOW-DOUBLE DIGITS.ADAPTIMMUNE - HAS RIGHT TO OPT IN TO A 50/50 U.S. PROFIT/COST SHARE ON "OFF-THE-SHELF" PRODUCTS.Further company coverage: ADAP.O. ((Reuters.Briefs@thomsonreuters.com;)).

Roche Receives FDA Approval For dMMR Solid Tumour Patient Diagnostic

Aug 18 (Reuters) - ROCHE HOLDING AG <ROG.S>::ROCHE RECEIVES FDA APPROVAL FOR FIRST COMPANION DIAGNOSTIC TO IDENTIFY DMMR SOLID TUMOUR PATIENTS ELIGIBLE FOR ANTI-PD-1 IMMUNOTHERAPY.

EMA Starts Evaluating Use Of Roactemra In Hospitalised Adults With Severe COVID-19

Aug 16 (Reuters) - European Medicines Agency::EMA: EMA STARTS EVALUATING USE OF ROACTEMRA IN HOSPITALISED ADULTS WITH SEVERE COVID-19: 16/08/2021.EMA SAYS EMA'S HUMAN MEDICINES COMMITTEE (CHMP) WILL CARRY OUT AN ACCELERATED ASSESSMENT OF DATA SUBMITTED IN APPLICATION.EMA: WILL COMMUNICATE ON THE OUTCOME OF ITS EVALUATION, WHICH IS EXPECTED BY MID-OCTOBER UNLESS SUPPLEMENTARY INFORMATION IS NEEDED..Further company coverage: ROG.S. ((Reuters.Briefs@thomsonreuters.com ;;)).

Roche says Polivy met primary endpoint of progression-free survival in trial

Aug 9 (Reuters) - Roche Holding AG <ROG.S>::PIVOTAL PHASE III POLARIX TRIAL COMPARING POLIVY IN COMBINATION WITH CHEMOTHERAPY REGIMEN R-CHP VERSUS STANDARD OF CARE R-CHOP IN TREATMENT OF FIRST-LINE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) MET ITS PRIMARY ENDPOINT OF INVESTIGATOR-ASSESSED PROGRESSION-FREE SURVIVAL.PROLONGING SURVIVAL WITHOUT DISEASE ADVANCEMENT COULD BE TRANSFORMATIVE FOR NEWLY DIAGNOSED DLBCL PATIENTS AS CURRENTLY 40% OF PATIENTS RELAPSE AFTER DISEASE PROGRESSION.DATA WILL BE SUBMITTED TO HEALTH AUTHORITIES GLOBALLY AS SOON AS POSSIBLE AND PRESENTED AT AN UPCOMING MEDICAL MEETING.

AnPac Bio And Roche Pharmaceuticals China Entered Into Cooperation

Aug 5 (Reuters) - AnPac Bio-Medical Science Co Ltd <ANPC.O>::ANPAC BIO AND ROCHE PHARMACEUTICALS CHINA ENTERED INTO COOPERATION TO EXPLORE INNOVATIVE HEALTHCARE AND MEDICAL SOLUTIONS.ANPAC BIO-MEDICAL SCIENCE - BOTH PARTIES PLAN TO UTILIZE CO'S CDA CANCER DETECTION TECHNOLOGY AND ROCHE'S FOUNDATIONONE CDX TO FORM A FULL SOLUTION.

FDA Accepts Application For Genentech's Faricimab

July 29 (Reuters) - Genentech: :FDA ACCEPTS APPLICATION FOR GENENTECH’S FARICIMAB FOR THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (AMD) AND DIABETIC MACULAR EDEMA (DME).FDA ACCEPTS APPLICATION FOR GENENTECH’S FARICIMAB FOR THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (AMD) AND DIABETIC MACULAR EDEMA (DME).GENENTECH- EUROPEAN MEDICINES AGENCY HAS ALSO VALIDATED FARICIMAB MARKETING AUTHORIZATION APPLICATION SUBMISSION IN WET AMD AND DME.

Roche CEO says demand for COVID-19 tests set to decline in H2

July 22 (Reuters) - :ROCHE CEO SAYS DEMAND FOR COVID-19 TESTS SET TO DECLINE IN SECOND HALF, ALTHOUGH MANY UNCERTAINTIES.ROCHE CEO SAYS HARD TO PREDICT IMPACT OF SPREAD OF DELTA VARIANT OF COVID-19, HOPES IT WON'T BE AS BIG AS FROM EARLIER WAVES.ROCHE CEO SAYS ONCOLOGY BUSINESS IS STILL NOT YET BACK TO PRE-PANDEMIC LEVELS.ROCHE SAYS MARKET SHARE PICKING UP VERY QUICKLY IN SMA TREATMENT.Further company coverage: ROG.S. (Reporting By Michael Shields). ((Michael.Shields@thomsonreuters.com;)).

Roche Says FDA Grants Breakthrough Therapy Designation For Venclexta In Combination With Azacitidine

July 21 (Reuters) - Roche Holding AG <ROG.S>::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR VENCLEXTA IN COMBINATION WITH AZACITIDINE FOR THE TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES.FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR VENCLEXTA IN COMBINATION WITH AZACITIDINE FOR TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES.EVERY YEAR IN US, APPROXIMATELY 10,000 PEOPLE ARE DIAGNOSED WITH MYELODYSPLASTIC SYNDROMES (MDS), AND THERE REMAINS A HIGH UNMET NEED FOR NEW TREATMENT OPTIONS1.DESIGNATION IS BASED ON INTERIM RESULTS FROM PHASE IB M15-531 STUDY INVESTIGATING VENCLEXTA/VENCLYXTO PLUS AZACITIDINE IN PEOPLE WITH PREVIOUSLY UNTREATED HIGHER-RISK MDS.THIS IS 11TH BREAKTHROUGH THERAPY DESIGNATION FOR ROCHE'S HAEMATOLOGY MEDICINES AND SIXTH FOR VENCLEXTA DEMONSTRATING ITS POTENTIAL ACROSS MULTIPLE BLOOD CANCERS.Further company coverage: ROG.S. (Berlin Speed Desk). ((frankfurt.newsroom@thomsonreuters.com;)).

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up